Elrexfio
Payments companies reported to CMS as associated with Elrexfio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Elrexfio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Elrexfio
These are the largest totals companies reported as associated with Elrexfio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Marc Braunstein | Hewlett, NY | Allergy | $878,400.00 |
| Shelbi Atrash | Charlotte, NC | Hematology & Oncology | $857,400.00 |
| Sanjeev Jain | East Patchogue, NY | Hematology & Oncology | $795,200.00 |
| Parameswaran Hari | Milwaukee, WI | Hematology & Oncology | $787,737.50 |
| Joseph Mikhael | Scottsdale, AZ | Hematology (Internal Medicine) | $626,700.00 |
| Ambrose Huang | Saint Louis, MO | Diagnostic Radiology | $163,670.00 |
| William Bensinger | Lakewood, WA | Medical Oncology | $106,231.47 |
| Ariel Grajales Cruz | Tampa, FL | Hematology & Oncology | $102,566.13 |
| Frank Simone | Indiana, PA | Diagnostic Radiology | $95,490.00 |
| Daniele Marin | Durham, NC | Diagnostic Radiology | $85,220.00 |
Prescribed Elrexfio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.